Last $164.20 USD
Change Today +4.29 / 2.68%
Volume 1.5M
SHPG On Other Exchanges
SHPG is not on other exchanges.
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24


Phone: 353 1 429 7700


as few as two tablets once daily. In 2012, the FDA issued draft bioequivalency guidance for orally-delivered delayed or extended-release mesalamine-based drugs. Following approvals in 2007 in the EU and Canada, as of December 31, 2012 LIALDA/MEZAVANT was commercially available in 19 countries either directly or through distributor arrangements. PENTASA PENTASA controlled release capsules are marketed by the company in the U.S. and are indicated for the induction of remission and for the treatment of patients with mild to moderately active UC. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the GI tract. PENTASA is available in the U.S. in 250mg and 500mg capsules. Treatments for GI diseases - chronic constipation RESOLOR RESOLOR is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists that stimulates GI motility and acts primarily on different parts of the lower GI tract (prokinetic). In 2009 RESOLOR was approved by the European Medicines Agency (EMA) throughout the EU as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults for whom the currently available treatment options involving dietary measures and laxatives do not provide sufficient effect. RESOLOR is available in 1mg and 2mg dose strengths, both for once-daily dosing. As of December 31, 2012 RESOLOR was available in 17 EU countries. In 2012, the company announced that it had acquired the rights to develop and market prucalopride in the U.S. pursuant to an agreement with Janssen Pharmaceutica N.V., part of the J&J Group. FOSRENOL FOSRENOL is a phosphate binder that is indicated for use in end-stage renal disease (stage 5) receiving dialysis and, from October 2009, is also indicated in the EU for the treatment of adult patients with CKD. Formulated as a chewable tablet, FOSRENOL is available in 500mg, 750mg and 1,000mg dosage strengths. The FDA approved the 500mg dosage strength in 2004 and the 750mg and 1,000 mg dosage strengths were approved in 2005. In 2009 FOSRENOL was launched in Japan. An oral powder formulation was approved and made available in certain European countries in 2012. XAGRID XAGRID is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. It was granted a marketing authorization in the EU in 2004. In the U.S., anagrelide hydrochloride is sold by the company under the trade name AGRYLIN for the treatment of thrombocythemia secondary to a myeloproliferative disorders. HGT REPLAGAL REPLAGAL is used for the treatment of Fabry disease. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate various clinical manifestations of Fabry disease. As of December 31, 2012, REPLAGAL was approved in 46 countries excluding the U.S. ELAPRASE ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). ELAPRASE was approved by the FDA in 2006 and granted marketing authorization by the EMA in 2007 for the long term treatment of patients with Hunter syndrome. ELAPRASE has been granted orphan drug exclusivity by both the FDA and the EMA, providing it with up to 7 and 10 years market exclusivity in the U.S. and EU, respectively. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan in 2007. As part of an agreement with Genzyme Corporation (Genzyme), Genzyme manages the sales and distribution of ELAPRASE in Japan, as well as certain other countries in the Asia Pacific region. As of December 31, 2012 ELAPRASE was approved in 51 countries. VPRIV (velaglucerase alfa) VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is a rare, inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $164.20 USD +4.29

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $203.51 USD -2.16
CSL Ltd A$67.94 AUD -0.07
Forest Laboratories Inc $91.65 USD -0.48
UCB SA €60.69 EUR +1.02
Valeant Pharmaceuticals International Inc C$146.99 CAD -2.39
View Industry Companies

Industry Analysis


Industry Average

Valuation SHPG Industry Range
Price/Earnings 22.0x
Price/Sales 6.0x
Price/Book 5.5x
Price/Cash Flow 46.9x
TEV/Sales 6.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at